The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Mezigdomide plus dexamethasone and bortezomib or carfilzomib in R/R myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the efficacy of the combination of mezigdomide plus dexamethasone and bortezomib or carfilzomib in relapsed/refractory (R/R) multiple myeloma. Dr Richardson highlights that the combination of mezigdomide with bortezomib generated response rates in excess of 70-80% and further shares the rationale for the ongoing SUCCESSOR-1 and SUCCESSOR-2 trials (NCT05519085; NCT05552976). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
